03/12/2025 08:00
EQS-News: Pentixapharm Advances Regulatory Preparations for Phase 3 PANDA Study with Radiodiagnostic Candidate 68Ga-PentixaFor in Hypertension
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Pentixapharm Holding AG / Key words: Study br/ Pentixapharm Advances Regulatory Preparations for Phase 3 PANDA Study with Radiodiagnostic Candidate 68GaPentixaFor in Hypertension news... Lire...
12/11/2025 08:00
EQS-News: Pentixapharm Publishes 9-Month Figures for 2025
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Pentixapharm Holding AG / Key words: 9 Month figures/Quarterly / Interim Statement br/ Pentixapharm Publishes 9Month Figures for 2025 br/br/ 12.11.2025 / 08:00... Lire...
10/11/2025 08:00
EQS-News: Pentixapharm to Report Third Quarter and First Nine Months 2025 Financial Results on Wednesday, November 12, 2025
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Pentixapharm Holding AG / Key words: 9 Month figures/Quarterly / Interim Statement br/ Pentixapharm to Report Third Quarter and First Nine Months 2025 Financial Results on Wednesday,... Lire...
06/11/2025 19:55
EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm significantly reduces projected loss for financial year 2025
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd pEQSAdhoc: Pentixapharm Holding AG / Key words: Annual Resultsbr/ Pentixapharm Holding AG: Pentixapharm significantly reduces projected loss for financial year 2025 br/br/ 06Nov2025 / 19:55 CET/CESTbr/ Disclosure... Lire...
23/10/2025 22:12
EQS-News: Pentixapharm Strengthens Pipeline Prioritization and Improves Cost Structure
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Pentixapharm Holding AG / Key words: Strategic Company Decision br/ Pentixapharm Strengthens Pipeline Prioritization and Improves Cost Structure br/br/ 23.10.2025 / 22:12... Lire...
23/10/2025 20:59
EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm Focuses Development on Advanced Clinical Programs and Strengthens Financial Position by Discontinuing Preclinical Activities
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd pEQSAdhoc: Pentixapharm Holding AG / Key words: Strategic Company Decisionbr/ Pentixapharm Holding AG: Pentixapharm Focuses Development on Advanced Clinical Programs and Strengthens Financial Position by Discontinuing... Lire...
06/10/2025 11:00
EQS-News: Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Pentixapharm Holding AG / Key words: Study results/Research Update br/ Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025... Lire...
26/09/2025 08:00
EQS-News: Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acute Myeloid Leukemia Trial
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Pentixapharm Holding AG / Key words: Study/Research Update br/ Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acute Myeloid Leukemia Trial news with... Lire...
27/05/2025 09:43
EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm outlines new clinical development strategy
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd pEQSAdhoc: Pentixapharm Holding AG / Key words: Studybr/ Pentixapharm Holding AG: Pentixapharm outlines new clinical development strategy br/br/ 27May2025 / 09:43 CET/CESTbr/ Disclosure of an inside information... Lire...